MAIA Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . MAIA Biotechnology
MAIA Stock  USD 2.38  0.01  0.42%   
MAIA Biotechnology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing MAIA Biotechnology's valuation are provided below:
Market Capitalization
88.5 M
Earnings Share
(0.74)
We have found one hundred four available fundamental ratios for MAIA Biotechnology, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of MAIA Biotechnology last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself in the future. As of January 30, 2026, Market Cap is expected to decline to about 38.4 M. In addition to that, Enterprise Value is expected to decline to about 27.8 M
Check MAIA Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MAIA Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.7 M, Interest Expense of 48.74 or Selling General Administrative of 6.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 11.43. MAIA financial statements analysis is a perfect complement when working with MAIA Biotechnology Valuation or Volatility modules.
  
Build AI portfolio with MAIA Stock
Check out the analysis of MAIA Biotechnology Correlation against competitors.
For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.

MAIA Biotechnology Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets8 M11.7 M4.6 M
Slightly volatile
Short and Long Term Debt Total273.9 K533.3 K204 K
Slightly volatile
Other Current Liabilities1.9 M2.7 M989.6 K
Slightly volatile
Total Current Liabilities3 M4.4 M1.6 M
Slightly volatile
Other Liabilities144.8 K272.8 K109.6 K
Slightly volatile
Current Deferred Revenue134.4 K128 K48.2 K
Slightly volatile
Accounts Payable1 M1.7 M581.8 K
Slightly volatile
Cash7.5 M11 M4.4 M
Slightly volatile
Cash And Short Term Investments7.5 M11 M4.4 M
Slightly volatile
Common Stock Shares Outstanding14.1 M25.5 M12.5 M
Slightly volatile
Liabilities And Stockholders Equity8 M11.7 M4.6 M
Slightly volatile
Non Current Liabilities Total3.2 M3.1 M789 K
Slightly volatile
Other Current Assets275.6 K544.9 K149.9 K
Slightly volatile
Other Stockholder Equity109.8 M104.5 M33.2 M
Slightly volatile
Total Liabilities4 M7.5 M2.2 M
Slightly volatile
Total Current Assets7.8 M11.7 M4.6 M
Slightly volatile
Short Term Debt134.4 K128 K58.2 K
Slightly volatile
Common Stock3.2 K3 K1 K
Slightly volatile
Long Term Debt345.4 K388.6 K424.2 K
Slightly volatile
Short and Long Term Debt25.6 K28.8 K31.4 K
Slightly volatile
Capital Stock3.2 K3 K1 K
Slightly volatile
Non Current Liabilities Other20 K22.5 K24.6 K
Slightly volatile
Non Currrent Assets Other2.4 K2.5 K475.4 K
Slightly volatile
Other Assets523.8 K589.2 K643.2 K
Slightly volatile
Net Receivables113.7 K69.6 K72.5 K
Slightly volatile
Deferred Long Term Liabilities521.3 K586.4 K640.1 K
Slightly volatile

MAIA Biotechnology Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.7 M5.7 M5.9 M
Slightly volatile
Selling General Administrative6.8 M8 M5.7 M
Slightly volatile
Selling And Marketing Expenses7.7 M10.4 M6.7 M
Slightly volatile
Other Operating Expenses13.7 M19.5 M10 M
Slightly volatile
Research Development6.8 M11.5 M4.3 M
Slightly volatile
Total Operating Expenses13.7 M19.5 M10 M
Slightly volatile
Interest Income384.4 K366.1 K65.6 K
Slightly volatile

MAIA Biotechnology Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation2.4 M1.7 M3.5 M
Slightly volatile
Begin Period Cash Flow6 M8.2 M3.7 M
Slightly volatile
Total Cashflows From Investing Activities150 K168.8 K184.2 K
Slightly volatile
Change To Operating Activities638.5 K368.3 K305.3 K
Slightly volatile
Total Cash From Financing Activities21.9 M20.9 M7 M
Slightly volatile
End Period Cash Flow7.5 M11 M4.4 M
Slightly volatile
Other Cashflows From Investing Activities150 K168.8 K184.2 K
Slightly volatile
Change To Netincome5.4 M7.7 M5.3 M
Slightly volatile
Dividends Paid46.6 K52.4 K57.2 K
Slightly volatile
Issuance Of Capital Stock11 M21.6 M4.9 M
Slightly volatile
Change To Inventory215.5 K242.5 K264.6 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Average Payables783.9 K1.3 M761.4 K
Slightly volatile
Cash Per Share0.450.390.3327
Slightly volatile
Income Quality0.390.610.3592
Slightly volatile
Net Debt To EBITDA0.650.470.7875
Slightly volatile
Current Ratio3.273.053.8728
Slightly volatile
Average Receivables186.3 K127.7 K170.6 K
Pretty Stable
Interest Debt Per Share0.00.00.0093
Pretty Stable
Debt To Assets0.590.560.262
Slightly volatile
Ebt Per Ebit0.931.231.0646
Slightly volatile
Quick Ratio3.273.053.8728
Slightly volatile
Net Income Per E B T0.770.890.9395
Pretty Stable
Cash Ratio3.152.883.7821
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9824
Slightly volatile
Debt Ratio0.590.560.262
Slightly volatile

MAIA Biotechnology Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap38.4 M50.5 M44.1 M
Slightly volatile
Enterprise Value27.8 M39.5 M33.8 M
Slightly volatile

MAIA Fundamental Market Drivers

MAIA Upcoming Events

22nd of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About MAIA Biotechnology Financial Statements

MAIA Biotechnology stakeholders use historical fundamental indicators, such as MAIA Biotechnology's revenue or net income, to determine how well the company is positioned to perform in the future. Although MAIA Biotechnology investors may analyze each financial statement separately, they are all interrelated. For example, changes in MAIA Biotechnology's assets and liabilities are reflected in the revenues and expenses on MAIA Biotechnology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in MAIA Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue128 K134.4 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VTIVanguard Total Stock
RIOTRiot Blockchain
TSLATesla Inc
When determining whether MAIA Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MAIA Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maia Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maia Biotechnology Stock:
How To Invest In MAIA
Details
Is MAIA Stock a good investment?
Details
What is MAIA Biotechnology's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of MAIA Biotechnology Correlation against competitors.
For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. Expected growth trajectory for MAIA significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive MAIA Biotechnology assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(0.74)
Return On Assets
(1.48)
Return On Equity
(26.91)
MAIA Biotechnology's market price often diverges from its book value, the accounting figure shown on MAIA's balance sheet. Smart investors calculate MAIA Biotechnology's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since MAIA Biotechnology's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that MAIA Biotechnology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MAIA Biotechnology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY